RNK07421

RNK07421 is a novel heterobifunctional small molecule developed by Ranok Therapeutics. It is designed to overcome resistance in cancers driven by the KRAS G12C mutation, which is prevalent in lung, colon, and pancreatic cancers. Unlike existing KRAS G12C inhibitors that often face resistance due to cancer cell adaptation, RNK07421 simultaneously targets both the mutant KRAS G12C protein and HSP90 (Heat Shock Protein 90), a chaperone protein that stabilizes multiple oncogenic proteins. By binding to both targets, RNK07421 disrupts oncogenic signaling pathways and degrades key proteins required for tumor growth and survival. Preclinical studies have shown that it suppresses ERK reactivation and reduces viability in resistant cancer cell lines as well as significantly shrinking tumors in animal models—outperforming monotherapies or combination therapies targeting only one pathway[1][2][3][5].